Li Dean Y
SEC CIK 1837016 · EDGAR
BoughtSold
Most active insiders at RXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Borgeson Blake | Dir | — | $4.10M |
| 2 | Gibson Christopher | Dir | — | $3.84M |
| 3 | Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| 4 | Taylor Ben R | CFO | — | $157.7K |
| 5 | Bumpus Namandje | Dir | — | $28.1K |
| 6 | Michor Franziska | Dir | — | — |
| 7 | Hallett David | CSO | — | — |
| 8 | Dar Zavain | Dir | — | — |
| 9 | Li Dean Y | Dir | — | — |
| 10 | Sun Elaine D | Dir | — | — |
Transactions 49
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-02 17:15 | 2026-07-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +3,747 | 1.47M | +0.3% | $0 | |
| 2026-06-22 16:32 | 2026-06-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +88.4K | 1.47M | +6% | $0 | |
| D | 2026-05-01 17:45 | 2026-04-29 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | M - OptEx | $110.03 | +4,722 | 96.8K | +5% | +$519.6K |
| D | 2026-05-01 17:45 | 2026-04-29 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | F - Tax | $110.03 | -2,326 | 94.4K | -2% | -$255.9K |
| 2026-04-02 16:56 | 2026-04-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +3,268 | 1.24M | +0.3% | $0 | |
| 2026-02-10 | 2026-02-10 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | S - Sale | $117.52 | -10.2K | 92.0K | -10% | -$1.20M | |
| D | 2026-02-06 | 2026-02-04 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | M - OptEx | $56.04 | +15.1K | 117.4K | +15% | +$845.5K |
| D | 2026-02-06 | 2026-02-04 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | S - Sale+OE | $118.77 | -15.1K | 102.3K | -13% | -$1.79M |
| 2026-01-28 | 2026-01-26 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | A - Grant | $107.40 | +20.5K | 102.3K | +25% | +$2.20M | |
| 2026-01-06 | 2026-01-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +2,381 | 1.24M | +0.2% | $0 | |
| 2025-10-03 | 2025-10-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,961 | 1.24M | +0.2% | $0 | |
| 2025-07-03 | 2025-07-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,949 | 1.24M | +0.2% | $0 | |
| D | 2025-06-23 | 2025-06-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +22.0K | 1.23M | +2% | $0 |
| 2025-04-03 | 2025-04-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +2,268 | 79.6K | +3% | $0 | |
| 2025-01-29 | 2025-01-27 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | A - Grant | $97.94 | +32.6K | 79.6K | +69% | +$3.19M | |
| 2025-01-06 | 2025-01-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,647 | 77.3K | +2% | $0 | |
| 2024-10-04 | 2024-10-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,925 | 75.7K | +3% | $0 | |
| 2024-07-03 | 2024-07-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,592 | 73.8K | +2% | $0 | |
| D | 2024-06-05 | 2024-06-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +13.1K | 72.2K | +22% | $0 |
| 2024-04-03 | 2024-04-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,267 | 59.1K | +2% | $0 | |
| D | 2024-02-12 | 2024-02-09 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | M - OptEx | $62.07 | +14.7K | 60.9K | +32% | +$912.6K |
| D | 2024-02-12 | 2024-02-09 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | S - Sale+OE | $125.50 | -14.7K | 46.2K | -24% | -$1.85M |
| 2024-01-24 | 2024-01-22 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | A - Grant | $119.43 | +25.8K | 46.2K | +126% | +$3.08M | |
| MI | 2024-01-11 | 2024-01-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | S - Sale | $13.66 | -29.0K | 422.0K | -6% | -$396.2K |
| 2024-01-04 | 2024-01-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,203 | 1.33M | +0.1% | $0 | |
| 2023-10-04 | 2023-10-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,659 | 1.33M | +0.1% | $0 | |
| I | 2023-10-04 | 2023-04-21 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | G - Gift | $0.00 | -627.7K | 0 | -100% | $0 |
| 2023-07-06 | 2023-07-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,609 | 637.5K | +0.3% | $0 | |
| D | 2023-06-21 | 2023-06-16 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +12.6K | 636.0K | +2% | $0 |
| D | 2023-05-03 | 2023-05-01 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | F - Tax | $115.47 | -524 | 20.5K | -2% | -$60.5K |
| D | 2023-05-03 | 2023-05-01 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | M - OptEx | $115.47 | +1,062 | 21.0K | +5% | +$122.6K |
| 2023-04-05 | 2023-04-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,724 | 623.4K | +0.3% | $0 | |
| 2023-01-25 | 2023-01-23 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | A - Grant | $109.88 | +3,275 | 19.9K | +20% | +$359.9K | |
| 2023-01-05 | 2023-01-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,573 | 621.7K | +0.3% | $0 | |
| 2022-10-05 | 2022-10-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,092 | 620.1K | +0.2% | $0 | |
| 2022-07-06 | 2022-07-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,409 | 619.0K | +0.2% | $0 | |
| D | 2022-06-16 | 2022-06-14 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +18.1K | 617.6K | +3% | $0 |
| D | 2022-05-04 | 2022-05-03 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | F - Tax | $87.65 | -381 | 16.5K | -2% | -$33.4K |
| D | 2022-05-04 | 2022-05-03 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | M - OptEx | $87.65 | +773 | 16.8K | +5% | +$67.8K |
| D | 2022-05-03 | 2022-05-01 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | F - Tax | $88.69 | -523 | 16.1K | -3% | -$46.4K |
| D | 2022-05-03 | 2022-05-01 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | M - OptEx | $88.69 | +1,061 | 16.6K | +7% | +$94.1K |
| 2022-04-05 | 2022-04-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +1,544 | 599.5K | +0.3% | $0 | |
| 2022-02-28 | 2022-02-24 | MRK | Merck & Co. | Li Dean Y | Pres, Executive VP, MRL | A - Grant | $73.51 | +3,023 | 15.5K | +24% | +$222.2K | |
| 2022-01-05 | 2022-01-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +659 | 597.9K | +0.1% | $0 | |
| MI | 2021-12-09 | 2021-12-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | S - Sale | $20.48 | -15.9K | 1.32M | -1% | -$325.6K |
| MAI | 2021-12-09 | 2021-11-17+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | S - Sale | $20.15 | -19.1K | 1.33M | -1% | -$384.9K |
| M | 2021-11-19 | 2021-11-17+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | S - Sale | $20.15 | -19.1K | 591.6K | -3% | -$384.9K |
| 2021-10-05 | 2021-10-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +543 | 597.3K | +0.1% | $0 | |
| 2021-07-06 | 2021-07-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Li Dean Y | Dir | A - Grant | $0.00 | +330 | 596.7K | +0.1% | $0 |
Purchase Sale Sale after option exercise All abbreviations